[三季报]健康元(600380):健康元药业集团股份有限公司2023年第三季度报告（英文版）
|
时间：2023年10月26日 14:42:54 中财网 |
|
原标题: 健康元: 健康元药业集团股份有限公司2023年第三季度报告（英文版）
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility. ? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the third quarterly financial statements have been audited. □Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the Reporting
Period
(From July to
September) | YoY change (%) | From the
beginning of the
year to the end of
the Reporting
Period | YoY change (%) | | Revenues | 3,931,515,787.21 | -11.59 | 12,651,257,386.44 | -2.77 | | Net profit attributable to
Shareholders of the listed
company | 268,214,419.85 | -17.55 | 1,083,649,154.75 | -3.81 | | Net profit attributable to
Shareholders of the listed
company after deduction of
extraordinary gains and losses | 267,477,595.49 | -14.37 | 1,049,221,737.67 | -6.01 | | Net cash flow from operating
activities | N/A | N/A | 2,459,851,744.70 | -5.72 | | Basic earnings per share
(RMB/share) | 0.1418 | -18.87 | 0.5682 | -5.03 | | Diluted earnings per share
(RMB/share) | 0.1412 | -18.83 | 0.5663 | -5.17 | | Weighted average return on
net assets (%) | 1.93 | Decreased by 0.80
percentage points | 8.22 | Decreased by1.16
percentage points | | | As at the end of the
Reporting Period | As at the end of the previous year | Change in the
ending amount of
the Reporting
Period to that of
the previous (%) | | | Total assets | 35,769,669,256.09 | 35,729,253,651.41 | 0.11 | | | Net assets attributable to
Shareholders of the listed
company | 13,337,938,211.52 | 13,121,820,410.55 | 1.65 | |
Notes: 1. The “Reporting Period” refers to the three-month period from the beginning to the end of this quarter,
the same below.
2. From January to September 2023, the Company Chemical pharmaceuticals realized revenues of RMB6,572 million, representing a YoY decrease of 9.20%, among which, RMB1,112 million were from respiratory formulation products, representing a YoY increase of 28.98%; RMB400 million were from anti-
infection products, representing a YoY decrease of 65.23%; RMB2,279 million were from gastroenterology
products, representing a YoY decrease of 12.93%; RMB2,188 million were from gonadotropic hormones, representing a YoY increase of 4.94%; and RMB430 million were from psychiatry products, representing a
YoY increase of 7.60%. APIs and intermediates products realized revenues of RMB3,970 million, representing
a YoY decrease of 2.07%. Traditional Chinese Medicine products realized revenues of RMB1,291 million,
representing a YoY increase of 49.48%. Diagnostic reagents and equipment products realized revenues of
RMB468 million, representing a YoY decrease of 6.88%. Health care products realized revenues of RMB132
million, representing a YoY increase of 60.12%. Biological products realized revenues of RMB113 million,
representing a YoY decrease of 31.09%.
3. From January to September 2023, the Company realized net profit attributable to shareholders of the
parent of RMB1,084 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit
attributable to shareholders of the parent of approximately RMB612 million, representing a YoY decrease of
approximately 4.17%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parent
was approximately negative RMB412 million.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the
Reporting Period | From the beginning of the
year to the end of the
Reporting Period | | Gains and losses on disposal of non-current assets | 141,880.83 | -200,478.63 | | Government grants as included in the profit or loss for the
Period, however, except for those which are closely related to
the normal business of an enterprise, comply with thepolicies of
the State and are continuously entitled with specific amount or
quantity according to certain standards | 25,392,502.84 | 148,737,247.12 | | Gains and losses on fair value changes incurred from financial
assets held for trading, derivative financial assets, financial
liabilities held for trading and derivative financial liabilities, and
investment income on disposal of financial assets held for
trading, derivative financial assets, financial liabilities held for
trading, derivative financial liabilities and other debt
investments, except for effective hedging activities related to the
ordinary operating business of the Company | -21,111,799.30 | -66,463,191.33 | | Other non-operating income and expenses excluding the above
items | -11,850,546.09 | -17,463,124.32 | | Less: Effect of income tax | 1,076,795.55 | 13,107,981.50 | | Effect of minority equity (after tax) | -9,241,581.63 | 17,075,054.26 | | Total | 736,824.36 | 34,427,417.08 |
Explanations for classifying items of extraordinary gains and losses defined in the Explanatory Announcement No. 1 for Public Company Information Disclosures –Extraordinary Gains or Losses as items of recurring gains or losses.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof □Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons Thereof
Unit: Yuan Currency: RMB
| Balance Sheet | 30 September
2023 | 31 December
2022 | Change in
proportion
（%） | Main Reason | | Financial assets held for
trading | 73,193,659.40 | 109,015,664.98 | -32.86 | Mainly due to fluctuations in
market value of the securities
investment held. | | Non-current assets due
within one year | 362,830,383.78 | 54,048,611.11 | 571.30 | Mainly due to an increase in
large-denomination of
deposit maturing within one
year. | | Construction in
progress | 562,135,145.68 | 811,300,068.96 | -30.71 | Mainly due to the production
lines of new factories and
workshops of the
subsidiaries transferred to
fixed assets. | | Financial liabilities held
for trading | 10,966,528.06 | 755,634.43 | 1,351.30 | Mainly due to the changes in
fair value of foreign currency
forward contracts. | | Contract liabilities | 75,564,862.24 | 292,977,730.74 | -74.21 | Mainly due to some contract
performance obligations
during the current period,
which satisfies the
conditions for revenues | | | | | | recognition and results in the
carrying forward of revenue. | | Other current liabilities | 45,432,846.70 | 101,276,714.35 | -55.14 | Mainly due to the decrease
in estimated refund payable. | | Lease liabilities | 14,438,999.56 | 23,482,486.07 | -38.51 | Mainly due to the decrease
in lease contracts signed
during the period, leading to
a decrease in lease payables. | | Treasury shares | 564,252,205.84 | 347,176,561.29 | 62.53 | Mainly due to the repurchase
of A shares of the Company
during the Period. | | Statement of Income | January to
September 2023 | January to
September 2022 | Change in
proportion
（%） | Main Reason | | Gains from changes in
fair values | -46,003,628.22 | -86,989,533.83 | N/A | Mainly due to fluctuations in
market value of the securities
investment held. | | Credit impairment loss | -17,737,505.85 | -9,508,656.53 | N/A | Mainly due to changes in the
aging of accounts
receivables, leading to the
corresponding increase in
expected credit loss during
the Period. | | Gains from disposal of
assets | -200,478.63 | 1,121,679.66 | -117.87 | Mainly due to gains incurred
from disposal of fixed assets
during the previous period. | | Non-operating expenses | 23,765,998.31 | 13,738,456.89 | 72.99 | Mainly due to the increase in
expenditure of charitable
donation for the period as
compared with the previous
period. | | Other comprehensive
income –net of tax | -22,658,520.87 | 80,412,282.94 | -128.18 | Mainly due to changes in the
fair value of other equity
instrument investments and
exchange rate fluctuations
resulting in changes in
translation differences of
foreign currency financial
statements. | | Cash Flow Statement | January to
September 2023 | January to
September 2022 | Change in
proportion
（%） | Main Reason | | Net cash flows from
financing activities | -1,987,651,014.91 | 873,841,344.96 | -327.46 | Mainly due to the issuance
of GDRs (Global Depository
Receipts) and the increase in
loans in the same period of
the previous year. |
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary
shares as of the end of the Reporting
Period | 79,393 | Total number of holders of preferred
shares with restored voting rights as of the
end of the Reporting Period (if any) | 0 |
| Shareholdings of the top 10 shareholders | | | | | | | | Name of shareholder | Nature of
shareholder | Number of
shares held | Percentage
(%) | Number of
shares held
with selling
restrictions | Pledge, mark or lock-up | | | | | | | | Share
status | Number | | Shenzhen Baiyeyuan Investment Co., Ltd.
(深圳市百业源投资有限公司) | Domestic non-
state-owned
legal person | 895,653,653 | 46.83 | 0 | Pledge | 75,679,725 | | Hong Kong Securities Clearing Company
Limited | Unknown | 94,148,526 | 4.92 | 0 | Unknown | | | Might Seasons Limited | Foreign legal
person | 35,929,699 | 1.88 | 0 | Unknown | | | Perseverance Asset Management L.L.P–
Gaoyi Xiaofeng No. 2 Zhixin Fund | Unknown | 16,561,348 | 0.87 | 0 | Unknown | | | China Foreign Economy and Trade Trust
Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng
Hongyuan Collection Fund Trust Plan | Unknown | 16,177,148 | 0.85 | 0 | Unknown | | | Huaxia Life Insurance Co., Ltd. - Own
fund | Unknown | 12,729,218 | 0.67 | 0 | Unknown | | | Abu Dhabi Investment Authority | Unknown | 10,232,971 | 0.54 | 0 | Unknown | | | Bank of Shanghai Co., Ltd.－Yinhua CSI
Innovative Drug Industry Trading Open-
end Index Securities Investment Fund | Unknown | 9,656,996 | 0.50 | 0 | Unknown | | | Agricultural Bank of China Limited -CSI
500 Exchange Traded Index Securities
Investment Fund | Unknown | 8,405,974 | 0.44 | 0 | Unknown | | | CPIC Fund -China Pacific Life Insurance
Co., Ltd. -with-profit insurance-CPIC
Fund China Pacific Life Equity Relative
Income (Guaranteed Dividend) single
assets management plan | Unknown | 7,558,834 | 0.40 | 0 | Unknown | | | Shareholdings of the top 10 shareholders without selling restrictions | | | | | | | | Name of shareholder | Number of tradable shares
held without selling
restrictions | Class and number of shares | | | | | | | | Class of shares | Number | | | | | Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
投资有限公司) | 895,653,653 | Ordinary shares
denominated in Renminbi | 895,653,653 | | | | | Hong Kong Securities Clearing Company Limited | 94,148,526 | Ordinary shares
denominated in Renminbi | 94,148,526 | | | | | Might Seasons Limited | 35,929,699 | Ordinary shares
denominated in Renminbi | 35,929,699 | | | | | Perseverance Asset Management L.L.P–Gaoyi Xiaofeng
No. 2 Zhixin Fund | 16,561,348 | Ordinary shares
denominated in Renminbi | 16,561,348 | | | | | China Foreign Economy and Trade Trust Co., Ltd.–Foreign
Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust
Plan | 16,177,148 | Ordinary shares
denominated in Renminbi | 16,177,148 | | | | | Huaxia Life Insurance Co., Ltd. - Own fund | 12,729,218 | Ordinary shares
denominated in Renminbi | 12,729,218 | | | | | Abu Dhabi Investment Authority | 10,232,971 | Ordinary shares
denominated in Renminbi | 10,232,971 | | | | | Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug
Industry Trading Open-end Index Securities Investment
Fund | 9,656,996 | Ordinary shares
denominated in Renminbi | 9,656,996 | | | | | Agricultural Bank of China Limited -CSI 500 Exchange
Traded Index Securities Investment Fund | 8,405,974 | Ordinary shares
denominated in Renminbi | 8,405,974 | | | | | CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-
profit insurance-CPIC Fund China Pacific Life Equity
Relative Income (Guaranteed Dividend) single assets
management plan | 7,558,834 | Ordinary shares
denominated in Renminbi | 7,558,834 | | | |
| Description of connection or acting-in-concert relationship
of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen
Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company,
and other shareholders; whether there is connection or acting-in-concert
relationship among other shareholders is unknown. | | Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
margin financing and securities lending and refinancing
business (if any) | N/A | | Description of the special repurchase account among the
top 10 shareholders | As of the end of the Reporting Period, the special repurchase account of the
Company (Special securities repurchase account of Joincare Pharmaceutical
Group Industry Co., Ltd.) owned 46,513,711 shares in total, accounting for
2.43%. |
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2023 | 31 December 2022 | | Current assets: | | | | Cash and bank balances | 14,411,629,365.32 | 14,808,488,110.96 | | Financial assets held for trading | 73,193,659.40 | 109,015,664.98 | | Notes receivable | 2,081,418,640.69 | 1,959,985,016.85 | | Accounts receivable | 2,939,748,117.45 | 3,103,758,850.15 | | Receivables financing | | | | Prepayments | 421,312,293.00 | 364,265,142.57 | | Other receivables | 64,768,235.54 | 52,535,740.14 | | Including: Interests receivable | | | | Dividends receivable | | | | Inventories | 2,717,381,235.93 | 2,561,869,999.57 | | Contract assets | | | | Assets held-for-sale | | | | Non-current assets due within one year | 362,830,383.78 | 54,048,611.11 | | Other current assets | 166,958,865.87 | 163,539,900.32 | | Total current assets | 23,239,240,796.98 | 23,177,507,036.65 | | Non-current assets: | | | | Debt investment | | | | Other debt investment | | | | Long-term receivables | | | | Long-term equity investment | 1,446,149,124.12 | 1,419,882,594.59 | | Other equity instrument investments | 1,141,445,217.03 | 1,193,958,879.05 | | Other non-current financial assets | | | | Investment properties | 6,191,475.43 | 6,191,475.43 | | Fixed assets | 5,683,766,148.57 | 5,265,200,110.91 | | Construction in progress | 562,135,145.68 | 811,300,068.96 | | Productive biological assets | | | | Oil and gas assets | | | | Right-of-use assets | 35,342,825.78 | 41,843,133.97 | | Intangible assets | 701,729,275.21 | 802,115,125.75 | | Development expenditures | 424,798,732.53 | 428,284,884.17 | | Goodwill | 636,339,503.82 | 614,468,698.73 | | Long-term prepaid expenses | 293,226,959.06 | 277,867,716.95 | | Deferred income tax assets | 531,621,736.93 | 533,861,743.26 | | Other non-current assets | 1,067,682,314.95 | 1,156,772,182.99 | | Total non-current assets | 12,530,428,459.11 | 12,551,746,614.76 | | Total assets | 35,769,669,256.09 | 35,729,253,651.41 | | Current liabilities: | | | | Short-term loans | 1,776,144,861.11 | 2,126,050,615.06 | | Financial liabilities held for trading | 10,966,528.06 | 755,634.43 | | Notes payable | 1,530,559,158.55 | 1,635,906,989.22 | | Accounts payable | 906,022,129.06 | 943,905,580.91 | | Receipts in advance | | | | Contract liabilities | 75,564,862.24 | 292,977,730.74 | | Employee benefits payable | 499,860,346.48 | 573,010,571.46 | | Taxes payable | 307,862,506.00 | 337,702,273.73 | | Other payables | 3,752,472,841.38 | 3,680,334,360.88 | | Including: Interests payable | | | | Dividends payable | 14,641,641.87 | 12,252,074.84 | | Liabilities held-for-sale | | | | Non-current liabilities due within one year | 71,269,180.31 | 63,077,260.98 | | Other current liabilities | 45,432,846.70 | 101,276,714.35 | | Total current liabilities | 8,976,155,259.89 | 9,754,997,731.76 | | Non-current liabilities: | | | | Long-term loans | 3,940,728,610.19 | 3,230,844,042.88 | | Bonds payable | | | | Lease liabilities | 14,438,999.56 | 23,482,486.07 | | Long-term payables | | | | Long-term payroll payable | | | | Estimated liabilities | | | | Deferred income | 412,897,139.98 | 384,537,267.55 | | Deferred income tax liabilities | 241,853,901.75 | 231,164,425.48 | | Other non-current liabilities | 90,000,000.00 | 84,000,000.00 | | Total non-current liabilities | 4,699,918,651.48 | 3,954,028,221.98 | | Total liabilities | 13,676,073,911.37 | 13,709,025,953.74 | | Owner's equity (or shareholder's equity): | | | | Paid-in capital (or Share capital) | 1,912,448,568.00 | 1,929,189,374.00 | | Other equity instruments | | | | Including: Preferred shares | | | | Perpetual debts | | | | Capital reserve | 2,044,380,284.45 | 2,343,693,215.99 | | Less: Treasury shares | 564,252,205.84 | 347,176,561.29 | | Other comprehensive income | 5,710,233.93 | 4,704,473.53 | | Special reserve | | | | Surplus reserve | 734,905,013.97 | 734,766,581.50 | | Undistributed profits | 9,204,746,317.01 | 8,456,643,326.82 | | Total owner's equity (or shareholder's equity)
attributable to the parent | 13,337,938,211.52 | 13,121,820,410.55 | | Minority shareholder's equity | 8,755,657,133.20 | 8,898,407,287.12 | | Total owner's equity (or shareholder's equity) | 22,093,595,344.72 | 22,020,227,697.67 | | Total liabilities and owner's equity (or
shareholder's equity) | 35,769,669,256.09 | 35,729,253,651.41 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Qiu Qingfeng
Consolidated Income Statement
From January to September, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters
(January to September)
of 2023 | First three quarters
(January to September)
of 2022 | | I. Total revenues | 12,651,257,386.44 | 13,011,966,738.16 | | Including: Operating revenues | 12,651,257,386.44 | 13,011,966,738.16 | | II. Total operating costs | 9,992,088,727.85 | 10,347,452,908.46 | | Including: Operating costs | 4,836,588,741.76 | 4,590,752,440.39 | | Tax and surcharges | 150,278,107.37 | 148,072,490.55 | | Selling expenses | 3,428,038,993.64 | 3,893,351,191.76 | | Administrative expenses | 680,009,158.86 | 813,143,493.11 | | R&D expenses | 1,211,596,866.40 | 1,232,505,100.33 | | Financial expenses | -314,423,140.18 | -330,371,807.68 | | Including: Interest expenses | 106,424,878.84 | 95,844,022.98 | | Interest income | 373,189,603.11 | 296,268,948.39 | | Add: Other income | 150,725,832.49 | 142,661,731.19 | | Investments income (“-” for loss) | 58,569,845.80 | 48,386,584.36 | | Including: Income from investments
in associates and joint ventures | 57,873,393.21 | 52,468,548.10 | | Gains from derecognition of financial
assets at amortized cost | | | | Gains from net exposure hedges (“-”
for loss) | | | | Gains from changes in fair values
(“-” for loss) | -46,003,628.22 | -86,989,533.83 | | Credit impairment loss (“-” for loss) | -17,737,505.85 | -9,508,656.53 | | Assets impairment loss (“-” for loss) | -108,440,945.45 | -142,159,872.24 | | Gains from disposal of assets (“-” for
loss) | -200,478.63 | 1,121,679.66 | | III. Operating profit (“-” for loss) | 2,696,081,778.73 | 2,618,025,762.31 | | Add: Non-operating income | 6,302,873.99 | 4,995,275.26 | | Less: Non-operating expenses | 23,765,998.31 | 13,738,456.89 | | IV. Total profit (“-” for loss) | 2,678,618,654.41 | 2,609,282,580.68 | | Less: Income tax expenses | 433,823,342.57 | 408,012,299.49 | | V. Net profit (“-” for loss) | 2,244,795,311.84 | 2,201,270,281.19 | | (I) Classified by business continuity | | | | 1. Net profit from continuing operation
(“-” for loss) | 2,244,795,311.84 | 2,201,270,281.19 | | 2. Net profit from discontinued
operation (“-” for loss) | | | | (II) Classified by ownership | | | | 1.Net profit attributable to shareholders
of the parent company (“-” for loss) | 1,083,649,154.75 | 1,126,561,953.23 | | 2.Profit and loss of minority
shareholders (“-” for loss) | 1,161,146,157.09 | 1,074,708,327.96 | | VI. Other comprehensive income, net of
tax | -22,658,520.87 | 80,412,282.94 | | (I) Other comprehensive income
attributable to owners of the parent, net
of tax | 1,005,760.40 | 31,984,064.97 | | 1. Other comprehensive income that
cannot be reclassified into profit or loss | -31,488,647.75 | 12,029,097.03 | | (1) Changes from remeasurement of
defined benefit plans | | | | (2) Other comprehensive income that
cannot be reclassified into profit or loss
under the equity method | 0.00 | 1,173,144.60 | | (3) Changes in fair value of
investments in other equity instruments | -31,488,647.75 | 10,855,952.43 | | (4) Changes in fair value of the
enterprise's own credit risks | | | | 2. Other comprehensive income that
will be reclassified into profit or loss | 32,494,408.15 | 19,954,967.94 | | (1) Other comprehensive income that
can be reclassified into profit or loss under
the equity method | 164,225.81 | 0.00 | | (2) Changes in fair value of other
debt investments | | | | (3) Amount of financial assets
reclassified into other comprehensive
income | | | | (4) Provision for credit impairment of
other debt investments | | | | (5) Reserve for cash flow hedges | | | | (6) Exchange translation differences
on financial statements denominated in
foreign currencies | 32,330,182.33 | 19,954,967.94 | | (7) Others | | | | (II) Other comprehensive income
attributable to minority shareholders, net
of tax | -23,664,281.27 | 48,428,217.97 | | VII. Total comprehensive income | 2,222,136,790.97 | 2,281,682,564.13 | | (I) Total comprehensive income
attributable to owners of the parent | 1,084,654,915.15 | 1,158,546,018.20 | | (II) Total comprehensive income
attributable to minority shareholders | 1,137,481,875.82 | 1,123,136,545.93 | | VIII. Earnings per share: | | | | (I) Basic earnings per share (RMB/share) | 0.5682 | 0.5983 | | (II) Diluted earnings per share
(RMB/share) | 0.5663 | 0.5971 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Qiu Qingfeng
Consolidated Cash Flow Statement
From January to September, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters
(January to September)
of 2023 | First three quarters
(January to September)
of 2022 | | I. Cash flows from operating activities: | | | | Cash received from sales of goods or rendering of
services | 13,510,230,759.20 | 13,705,807,329.89 | | Tax refunds received | 141,490,762.85 | 219,263,256.92 | | Other cash received related to operating activities | 620,955,869.98 | 536,180,845.96 | | Subtotal of cash inflow from operating
activities | 14,272,677,392.03 | 14,461,251,432.77 | | Cash paid for goods and services | 4,573,141,561.87 | 4,180,212,054.68 | | Cash paid to and on behalf of employees | 1,764,671,591.22 | 1,797,221,409.89 | | Payments of all types of taxes | 1,416,153,712.56 | 1,293,188,165.95 | | Other cash paid related to operating activities | 4,058,858,781.68 | 4,581,637,269.28 | | Subtotal of cash outflow in operating activities | 11,812,825,647.33 | 11,852,258,899.80 | | Net cash flows from operating activities | 2,459,851,744.70 | 2,608,992,532.97 | | II. Cash flows from investing activities: | | | | Cash received from disposal of investments | 390,344,459.46 | 216,970,980.42 | | Cash received from investment income | 70,124,524.03 | 121,905,782.77 | | Net cash received from disposal of fixed assets,
intangible assets and other long-term assets | 8,042,426.01 | 1,307,684.20 | | Net cash received from disposal of subsidiaries
and other business units | | | | Other cash received related to investing activities | 297,590,000.00 | 13,356,765.87 | | Subtotal of cash inflows from investing
activities | 766,101,409.50 | 353,541,213.26 | | Cash paid for purchase and construction of fixed
assets, intangible assets and other long-term assets | 753,228,828.13 | 975,980,046.68 | | Cash paid to acquire investments | 439,136,113.68 | 37,995,968.80 | | Net cash paid for acquisition of subsidiaries and
other business units | 22,461,951.59 | 0.00 | | Other cash paid related to investing activities | 227,027,492.56 | 226,494,395.22 | | Subtotal of cash outflows in investing activities | 1,441,854,385.96 | 1,240,470,410.70 | | Net cash flows from investing activities | -675,752,976.46 | -886,929,197.44 | | III. Cash flows from financing activities: | | | | Cash received from capital contribution | 18,056,784.20 | 719,365,346.09 | | Including: Cash received from investment by
minority interests of subsidiaries | 6,700,000.00 | 0.00 | | Cash received from borrowings | 3,347,170,168.70 | 5,297,022,796.00 | | Other cash received related to financing activities | 20,000,000.00 | 303,958,487.50 | | Subtotal of cash inflows from financing
activities | 3,385,226,952.90 | 6,320,346,629.59 | | Cash repayments of amounts borrowed | 2,592,352,425.04 | 3,504,080,892.47 | | Cash payments for interest expenses and
distribution of dividends or profits | 1,570,166,936.38 | 1,314,118,888.43 | | Including: Dividends and profit paid to minority
interests of subsidiaries | 1,120,761,303.69 | 960,193,396.67 | | Other cash payments related to financing
activities | 1,210,358,606.39 | 628,305,503.73 | | Subtotal of cash outflows from financing
activities | 5,372,877,967.81 | 5,446,505,284.63 | | Net cash flows from financing activities | -1,987,651,014.91 | 873,841,344.96 | | IV. Effect of exchange rate changes on cash and
cash equivalents | 71,991,155.94 | 227,244,304.84 | | V. Net increase in cash and cash equivalents | -131,561,090.73 | 2,823,148,985.32 | | Add: Opening balance of cash and cash
equivalents | 14,178,465,686.40 | 11,697,518,141.18 | | VI. Closing balance of cash and cash equivalents | 14,046,904,595.67 | 14,520,667,126.50 |
（未完）
|
|
